MG
FATE icon

Michael Gelband’s Fate Therapeutics FATE Stock Holding History

Michael Gelband’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80,670
Closed -$282K – 1673
2024
Q3 		$282K Buy
+80,670
New +$314K ﹤0.01% 1379
2024
Q1 		– Sell
-31,185
Closed -$117K – 1628
2023
Q4 		$117K Buy
31,185
+12,154
+64% +$28.7K ﹤0.01% 1342
2023
Q3 		$40K Sell
19,031
-5,220
-22% -$17.3K ﹤0.01% 1617
2023
Q2 		$115K Sell
24,251
-72,984
-75% -$403K ﹤0.01% 1747
2023
Q1 		$554K Sell
97,235
-148,523
-60% -$896K ﹤0.01% 1309
2022
Q4 		$2.48M Buy
245,758
+220,284
+865% +$4.14M 0.04% 565
2022
Q3 		$571K Buy
+25,474
New +$736K 0.01% 1320
2021
Q4 		– Sell
-13,686
Closed -$811K – 2294
2021
Q3 		$811K Buy
13,686
+3,666
+37% +$288K 0.01% 1124
2021
Q2 		$870K Buy
+10,020
New +$807K 0.01% 1075
2021
Q1 		– Sell
-13,651
Closed -$1.24M – 2248
2020
Q4 		$1.24M Buy
+13,651
New +$848K 0.01% 745
2020
Q2 		– Sell
-12,014
Closed -$267K – 1842
2020
Q1 		$267K Buy
+12,014
New +$304K 0.01% 690

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Michael Gelband's FATE Position: Q4 2024 in Review

Michael Gelband sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 80,670 shares — an estimated $282K sold.

Michael Gelband first reported a position in FATE in Q1 2020 and held it in 11 quarters. The position peaked at $2.48M in Q4 2022. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Michael Gelband reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 80,670 Fate Therapeutics shares in Q4 2024, an estimated $282K.
  • Michael Gelband first reported a position in Fate Therapeutics in Q1 2020 and held it in 11 quarters.
  • Michael Gelband's Fate Therapeutics position peaked at $2.48M in Q4 2022.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.